<?xml version="1.0" encoding="UTF-8"?>
<p id="Par113">The DSMC may recommend the early termination of the trial if one of the following conditions is met: an unacceptable toxicity or all available data from the trial or any other source of information are sufficiently convincing to influence the therapeutical practices of the majority of clinicians. The DSMC has only a consultative role; it will inform the sponsor who will decide whether the DSMC recommendation will be followed. An adverse event (AE) is defined as any untoward medical occurrence, in a patient or clinical trial subject treated by a medicinal product and which does not necessarily have a causal relationship with this treatment. The assessment of whether there is a reasonable causal relationship is made by the investigator. Notification must be carried out immediately by fax to the R&amp;D UNICANCER pharmacovigilance unit by sending the form "notification of a Serious Adverse Effects‚Äù, located in the Investigator Master File, completed as precisely as possible, dated and signed by the physician-investigator.</p>
